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Abstract
Antitumor activities of five platinum analogs, including cisplatin, carboplatin, 254-S, DWA2114R,
and NK121, were compared using five human lung cancer cell lines and 19 tumor specimens ob-
tained from lung cancer patients. The antitumor activity was evaluated by determining the ratio of
the maximum tolerated dose of each drug to the 70% tumor growth inhibitory concentration in a
colony assay. Cisplatin was the most potent agent, followed by 254-S and carboplatin. DWA2114R
and NK121 were less potent than cisplatin and 254-S. Cross-resistance to adriamycin was also
investigated using an adriamycin-resistant small cell lung cancer subline, SBC -3/ADM30. SBC-
3/ADM30 was 1.7- to 4.0-fold more resistant to cisplatin, carboplatin, NK121, and DWA2114R,
than was the parent line, SBC-3, and the subline was 2.0-fold more sensitive to 254-S. Using SBC-
3, in vitro combination effects of etoposide and cisplatin, carboplatin, or 254-S were evaluated by
the median-effect principle. Synergism was noted when cisplatin and etoposide were combined at
a fixed molar ratio of 1:1. Combination of carboplatin and etoposide showed an additive effect.
The combination of 254-S and etoposide was antagonistic at low concentrations, but was markedly
synergistic at higher concentrations. These data suggested the efficacy of 254-S in the treatment
of lung cancer.
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